RxDoctor Payments Data

Trisha Plastini, DO

Hematology & Oncology · West Palm Beach, FLNPI 1619313798

Payments from drug & device makers

$1,590in general payments, 2019–2025

Across 58 payments — averaging $27.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bristol Myers Squibb$351
  • Pfizer$225
  • AstraZeneca$155
  • Seagen Inc.$138
  • Rigel Pharmaceuticals, Inc.$125
  • Novartis$116
  • plus $481 from 9 others

What the payments were for

  • Food & beverage$1,32183%
  • Education$26917%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,590 in reported general payments places this provider in the 25th percentile of 694 hematology & oncology providers in Florida.

See all hematology & oncology providers in Florida

Medicare billing

Part B allowed, 2024
$3,522,447
Medicare patients
340
Services billed
158,109

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JakafiRuxolitinib Phosphate52$1,169,333
XtandiEnzalutamide56$694,415
ImbruvicaIbrutinib27$446,788
CalquenceAcalabrutinib Maleate27$387,116
Lenalidomide22$324,478
InlytaAxitinib12$218,047
NubeqaDarolutamide14$188,562
Abiraterone Acetate73$120,235
Imatinib Mesylate12$29,704
EliquisApixaban25$23,986
XareltoRivaroxaban11$9,617
Voriconazole11$2,510
Fentanyl12$1,302
Hydroxyurea48$1,211
Methadone Hcl12$962

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaCalquence$155$387,11627 claims
PfizerInlyta, Eliquis$225$242,03337 claims
Johnson & JohnsonXarelto$103$9,61711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 694 hematology & oncology providers in Florida.

Other hematology & oncology in West Palm Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →